[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_54":55,"_56":57,"_58":59,"_60":61,"_62":63,"_64":65,"_66":67},"routes/blogs.$blogHandle._index",{"_9":10},"blog",{"_11":12,"_13":14,"_15":16,"_17":18},"title","News","handle","news","seo",{"_11":-5,"_53":-5},"articles",{"_19":20,"_21":22},"nodes",[30,31],"pageInfo",{"_23":24,"_25":24,"_26":27,"_28":29},"hasPreviousPage",false,"hasNextPage","endCursor","eyJsYXN0X2lkIjo1NzQyOTIwOTkyNzAsImxhc3RfdmFsdWUiOjU3NDI5MjA5OTI3MCwib2Zmc2V0IjoxfQ==","startCursor","eyJsYXN0X2lkIjo1NzMzMzMwMTI2NzgsImxhc3RfdmFsdWUiOjU3MzMzMzAxMjY3OCwib2Zmc2V0IjowfQ==",{"_32":46,"_34":47,"_13":48,"_37":49,"_39":-5,"_40":50,"_11":51,"_9":52},{"_32":33,"_34":35,"_13":36,"_37":38,"_39":-5,"_40":41,"_11":42,"_9":43},"author",{"_44":45},"contentHtml","

Why Your ADHD Medication Stopped Working: The Estrogen-Dopamine Connection

Published by Finally. | Research & Science

You were managing. Maybe not perfectly, but you had systems. The medication helped. You knew your brain, you had built a life around how it worked, and then somewhere down the line, you felt changes. The Adderall that used to carry you through a full workday started wearing off by noon. The Vyvanse that once felt like clarity started feeling like a drop in the ocean. Upping the dose will work, sure. For now, but how long until you need to get it increased? Then again? Do you need to wait for it to stop working or look for a new solution?

Nobody told you this was coming, not on top of the heat flashes and 3am wakeups. Who would tie together the same reason that you were unable to pull a word from your brain in the middle of a sentence would be the same reason you needed to leave a book on your pillow to make sure you would read before bed.

You may have suspected it. But you never had the biology to tie it together so your doctor could see through the same lens as you. Here is what you've been feeling.

Estrogen Is Not a Reproductive Hormone. It Is a Brain Hormone.

This is the framing error that leaves most women without answers. Estrogen is classified and discussed primarily in the context of reproduction, which means that when reproduction winds down, the medical conversation about estrogen winds down with it. Your OB-GYN focuses on menstrual cycles and hot flashes. Your psychiatrist focuses on your ADHD symptoms. Nobody is sitting at the intersection, looking at what estrogen was doing to your brain before it started declining.

Estrogen receptors are distributed throughout the central nervous system. They are found in the prefrontal cortex, the hippocampus, the amygdala, and critically, in the dopaminergic pathways that run through the brain's reward and executive function systems (McEwen et al., 2012). Estrogen is not a visitor in these regions. It is a structural participant in how they function.

The relationship between estrogen and dopamine is not incidental. Estradiol, the most potent form of estrogen and the one that declines most sharply during perimenopause, does several things to dopamine simultaneously:

It stimulates dopamine synthesis in the prefrontal cortex. It slows dopamine breakdown by inhibiting the enzyme monoamine oxidase B (MAO-B). It upregulates dopamine receptor density, specifically D1 and D2 receptors, in regions governing attention, working memory, and impulse control. And it enhances dopamine transporter function, regulating how efficiently dopamine is recycled at the synapse (Dluzen & Bhatt, 2008; Yoest et al., 2014).

What this means practically: when estradiol is present at healthy premenopausal levels, the dopaminergic system runs with a degree of structural support that most women never notice because it has always been there. The medication works. The coping strategies work. The systems you built hold.

When estradiol starts declining in perimenopause, that structural support begins to erode. Not immediately, not catastrophically, but progressively. The scaffolding comes down slowly enough that the connection is rarely made.

What ADHD Looks Like on a Dopamine System That Is Losing Its Scaffolding

Attention deficit hyperactivity disorder is fundamentally a disorder of dopamine regulation in the prefrontal cortex. The current neurobiological consensus is that ADHD involves reduced dopaminergic tone in circuits governing executive function, working memory, sustained attention, and impulse inhibition (Arnsten, 2006; Faraone et al., 2021).

Stimulant medications work by increasing the availability of dopamine and norepinephrine at the synapse. They do not fix the underlying architecture. They compensate for it by flooding the system with more neurotransmitter than it would otherwise have available.

Now consider what happens when the system that was quietly supporting your dopamine signaling for three decades begins to withdraw.

The stimulant dose that was adequate when estradiol was providing structural reinforcement is no longer adequate when that reinforcement is gone. The medication has not changed. The baseline it is compensating for has changed. You need more stimulant to achieve the same functional outcome, not because your ADHD has gotten worse, but because the hormonal environment that was quietly helping manage it has shifted underneath you.

Physicians who are not tracking this intersection will typically respond to medication failure in perimenopause by adjusting the dose upward, changing the formulation, or reconsidering the diagnosis. What they should be asking is: what changed around the time this stopped working? In many women, the answer is that perimenopause started.

The Late Diagnosis Problem

There is a related issue that deserves its own discussion. Many women in their 40s are being diagnosed with ADHD for the first time, not because they did not have it previously, but because they were previously managing it without knowing that is what they were doing.

Research consistently shows that ADHD is underdiagnosed in girls and women relative to boys and men (Quinn & Madhoo, 2014). Girls with ADHD tend to present with inattentive rather than hyperactive symptoms, develop more robust compensatory strategies, and are less likely to be flagged in clinical or educational settings. Many spend decades being described as bright but disorganized, or capable but scattered, or sensitive and prone to anxiety, without anyone looking at the underlying neurology.

What held the compensatory strategies together, in many cases, was estradiol. High-performing women with undiagnosed ADHD frequently describe their late 30s and early 40s as a period of maximum capacity. They had decades of practiced coping mechanisms, and they had robust estrogen levels supporting their dopamine system. When perimenopause arrives and estradiol begins its decline, the compensatory strategies start failing. Executive dysfunction that was previously managed through structure, habit, and sheer cognitive effort becomes unmanageable. Women who never struggled significantly in professional environments suddenly cannot complete tasks, cannot maintain focus through a meeting, cannot hold a train of thought long enough to finish a sentence.

This is when the diagnosis comes. The first ADHD diagnosis in a 47-year-old woman is frequently not a case of ADHD appearing in midlife. It is a case of ADHD becoming visible in midlife because the hormonal buffer that was masking it has been withdrawn.

The NAD+ Layer

The estrogen-dopamine relationship is not the only mechanism at work here. There is a second pathway that compounds the cognitive impairment, and it runs through cellular energy metabolism.

Nicotinamide adenine dinucleotide, or NAD+, is the coenzyme your cells use to produce ATP, the energy currency of the body. NAD+ is present in every cell and is essential to mitochondrial function, DNA repair, and cellular resilience. It declines with age, but the rate of that decline accelerates significantly during perimenopause through a specific enzyme-mediated mechanism.

CD38 is an enzyme that consumes NAD+. It is involved in immune signaling and calcium regulation, and under normal circumstances its activity is modulated by several factors, including estrogen. When estradiol levels decline, CD38 activity is upregulated (Camacho-Pereira et al., 2016). More CD38 means more NAD+ consumed. More NAD+ consumed means less available for mitochondrial energy production. Less mitochondrial energy production in the brain means neurons that are already under dopaminergic stress are now also running on reduced cellular fuel.

The prefrontal cortex, the region most implicated in ADHD and executive function, is among the most metabolically demanding regions in the brain. It requires sustained, reliable ATP production to maintain the neuronal activity that supports working memory, attention, and cognitive control. When NAD+ depletion reduces the mitochondria's capacity to produce ATP at the required rate, prefrontal function is among the first to degrade.

This is not a separate problem from the dopamine issue. It is the same problem at a different level of biology. The dopaminergic scaffolding is being withdrawn by estrogen decline. The cellular energy supply is being reduced by NAD+ depletion. Both are happening simultaneously, driven by the same underlying hormonal shift. The result is a cognitive system that is being squeezed from two directions at once.

Yoshino et al. (2021) conducted the first randomized controlled trial of NMN supplementation specifically in perimenopausal and postmenopausal women, published in Science. The study found that NMN supplementation at 250mg per day for 10 weeks increased skeletal muscle NAD+ levels and improved insulin sensitivity, suggesting that NAD+ restoration through precursor supplementation is achievable in this population. The cognitive implications of sustained NAD+ restoration in this demographic remain an active area of research, but the metabolic findings establish the baseline: NAD+ depletion in perimenopausal women is real, measurable, and responsive to precursor intervention.

The Dopamine-NAD+ Intersection in Executive Function

Dopamine synthesis itself is an energy-dependent process. The enzymes involved in converting tyrosine to dopamine, including tyrosine hydroxylase and DOPA decarboxylase, require cofactors and cellular energy to function (Meiser et al., 2013). A neuron that is low on NAD+ and producing insufficient ATP is a neuron that cannot synthesize dopamine efficiently regardless of how much precursor substrate is available.

This creates a compounding failure loop. Estrogen decline reduces dopaminergic tone directly through receptor downregulation and reduced synthesis stimulation. Estrogen decline also accelerates NAD+ depletion through CD38 upregulation. Reduced NAD+ impairs the cellular energy supply neurons need to synthesize dopamine efficiently. The result is a dopamine system that is under-supported at the structural level and under-resourced at the metabolic level simultaneously.

Stimulant medications address neither of these root causes. They compensate for reduced dopamine availability by increasing synaptic dopamine concentrations through reuptake inhibition or increased release. But if the neurons themselves are less capable of producing dopamine due to metabolic constraint, and if the receptor environment is less sensitive due to reduced estradiol support, the stimulant is working against a structural deficit it was not designed to address.

Why This Is Not in Your Doctor's Head

The 2019 North American Menopause Society position statement notes that physician knowledge of menopause management is inconsistent and frequently inadequate, with surveys suggesting that fewer than 7% of residents in relevant specialties feel prepared to support menopausal patients (Kling et al., 2019).

The ADHD side of this picture is equally fragmented. Psychiatric training in ADHD has historically centered on pediatric populations and adult males. The presentation of ADHD in adult women, particularly the inattentive subtype that predominates in female patients, has received comparatively little attention in clinical training curricula (Quinn & Madhoo, 2014). The intersection of hormonal transition and ADHD neurobiology is a subject that falls between specialties. Your psychiatrist is not thinking about your estradiol levels. Your OB-GYN is not thinking about your dopamine receptors. The result is that the connection between perimenopausal hormonal change and ADHD symptom exacerbation is missed in the vast majority of clinical encounters.

This is not a failure of individual physicians. It is a structural gap in how medicine has historically organized its knowledge about women's health across the lifespan. Research by Saltz (2025), published in Frontiers in Psychology, documents the phenomenon of age-related gendered diminishment in post-midlife women, describing the psychological consequences of a medical and social system that consistently fails to prepare women for or adequately support them through the cognitive and emotional changes of the menopausal transition.

What the Research Actually Supports

The direct research on estrogen-ADHD interactions in perimenopausal women is, frankly, thin. This is consistent with the broader pattern of underinvestment in female-specific neurology and women's health research that Criado Perez (2019) documented extensively in her analysis of how medical research has treated women as default male bodies with hormonal variation.

What the research does support clearly:

Estradiol modulates dopamine synthesis, receptor expression, and metabolic efficiency in the prefrontal cortex and striatum (McEwen et al., 2012; Yoest et al., 2014). Dopaminergic dysregulation is the primary neurobiological mechanism of ADHD (Faraone et al., 2021). NAD+ depletion during perimenopause is mediated by estrogen withdrawal and CD38 upregulation (Camacho-Pereira et al., 2016). Dopamine synthesis is metabolically dependent on cellular energy availability (Meiser et al., 2013). NMN supplementation can restore NAD+ levels in perimenopausal and postmenopausal women (Yoshino et al., 2021).

The mechanistic chain connecting these findings is coherent and consistent with the clinical experience reported by large numbers of perimenopausal women with ADHD. The absence of clinical trials specifically testing ADHD symptom outcomes in the context of estrogen-NAD+ restoration does not mean the connection does not exist. It means the research has not yet caught up to the biology.

What This Means Practically

If your ADHD medication stopped working in your 40s, the first questions worth asking are not about dose adjustments or alternative stimulant formulations. They are about what changed in your hormonal and metabolic environment around the time the medication started failing.

Hormone replacement therapy, where appropriate and accessible, addresses the estradiol component of this picture directly. The research on HRT and cognitive function in perimenopausal women is extensive and generally supportive, particularly for women who initiate HRT within the critical window around the onset of perimenopause (Kling et al., 2019). This is a conversation worth having with a physician who understands perimenopause and is not dismissive of the cognitive symptoms.

The NAD+ component is addressable through precursor supplementation. NMN and nicotinamide riboside (NR) both serve as precursors to NAD+ through different metabolic pathways, and both have been studied in the context of NAD+ restoration in aging populations (Yoshino et al., 2021; Trammell et al., 2016). The relevant consideration in the context of perimenopause is targeting the specific depletion mechanism: it is not simply that NAD+ declines with age, but that estrogen withdrawal accelerates that decline through CD38 upregulation, creating a depletion rate that exceeds what normal aging would produce.

This is why generic NAD+ supplements marketed for aging do not specifically serve this demographic. The mechanism is not generic age-related NAD+ decline. It is hormonally mediated, enzyme-driven, and specific to the estrogen withdrawal of perimenopause.

The final practical point is the most important one. If you have spent months or years describing these cognitive changes to physicians who attributed them to stress, anxiety, normal aging, or depression, you are not the exception. You are the rule. The medical system has not been adequately prepared to see the intersection of hormonal transition and neurodevelopmental variation in adult women. The absence of a diagnosis or explanation does not mean there is no biological basis for what you are experiencing. The biology is well established. The clinical awareness has not kept pace with it.

References

Arnsten, A. F. T. (2006). Fundamentals of attention-deficit/hyperactivity disorder: Circuits and pathways. Journal of Clinical Psychiatry, 67(Suppl 8), 7-12.

Camacho-Pereira, J., Tarrago, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., Puranik, A. S., Schoon, R. A., Reid, J. M., Galina, A., & Chini, E. N. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006

Criado Perez, C. (2019). Invisible women: Exposing data bias in a world designed for men. Chatto & Windus.

Dluzen, D. E., & Bhatt, S. (2008). Effects of estrogen and the 5-HT3 receptor on dopamine-stimulated methamphetamine-induced changes in locomotor behavior. Neuropharmacology, 55(2), 140-147. https://doi.org/10.1016/j.neuropharm.2008.05.006

Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., Rohde, L. A., Yang, L., Cortese, S., Almagor, D., Stein, M. A., Albatti, T. H., Aljoudi, H. F., Alqahtani, M. M. J., Asherson, P., ... Wang, Y. (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 128, 789-818. https://doi.org/10.1016/j.neubiorev.2021.01.022

Kling, J. M., MacLaughlin, K. L., Schnatz, P. F., Crandall, C. J., Skinner, L. J., Bhagra, A., & Faubion, S. S. (2019). Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents: A cross-sectional survey. Mayo Clinic Proceedings, 94(2), 242-253. https://doi.org/10.1016/j.mayocp.2018.08.033

McEwen, B. S., Akama, K. T., Spencer-Segal, J. L., Milner, T. A., & Waters, E. M. (2012). Estrogen effects on the brain: Actions beyond the hypothalamus via novel mechanisms. Behavioral Neuroscience, 126(1), 4-16. https://doi.org/10.1037/a0026708

Meiser, J., Weindl, D., & Hiller, K. (2013). Complexity of dopamine metabolism. Cell Communication and Signaling, 11(1), 34. https://doi.org/10.1186/1478-811X-11-34

Quinn, P. O., & Madhoo, M. (2014). A review of attention-deficit/hyperactivity disorder in women and girls: Uncovering this hidden diagnosis. The Primary Care Companion for CNS Disorders, 16(3). https://doi.org/10.4088/PCC.13r01596

Saltz, R. (2025). Age-related gendered diminishment: Toward understanding and interventions for a common psychological experience in post-midlife women. Frontiers in Psychology, 16, 1535145. https://doi.org/10.3389/fpsyg.2025.1535145

Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jakobsson, A., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. https://doi.org/10.1038/ncomms12948

Yoshino, M., Yoshino, J., Kayser, B. D., Patti, G. J., Franczyk, M. P., Mills, K. F., Sindelar, M., Pietka, T., Patterson, B. W., Imai, S., & Klein, S. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. https://doi.org/10.1126/science.abe9985

Yoest, K. E., Cummings, J. A., & Becker, J. B. (2014). Estradiol, dopamine and motivation. Central Nervous System Agents in Medicinal Chemistry, 14(2), 83-89. https://doi.org/10.2174/1871524914666141226103135

","why-your-adhd-medication-stopped-working-the-estrogen-dopamine-connection","id","gid://shopify/Article/574292099270","image","publishedAt","2026-07-01T01:45:39Z","Why Your ADHD Medication Stopped Working: The Estrogen-Dopamine Connection",{"_13":14},"name","Ayden Miller",{"_44":45},"

\n\n\n

Cognitive Health · NAD⁺ Science

Why Your Brain
Feels Different
After 40.

\nBrain fog. Lost words. Slow processing.\n

\nThis isn't aging. Here's what it actually is.\n

You're sitting in a meeting and the word disappears mid-sentence. You read the same paragraph three times and it doesn't land. By 2pm your brain is done, even when your body isn't. You used to be the sharpest person in the room. Now you're compensating, and hoping nobody notices.

This is not aging. This is not stress. This is not you becoming less capable. There is a specific, measurable biological mechanism happening in your cells right now — and the fact that nobody has explained it to you is a failure of medicine, not a reflection of your intellect.

Here is what is actually going on.

The mechanism

Estrogen Does More Than You Were Told

Most women are taught that estrogen governs reproduction. What most women are never told is that estrogen also plays a critical role in brain energy metabolism. Estradiol — the primary form of estrogen — is one of the body's most important regulators of mitochondrial efficiency. When it drops, an entirely separate system begins to fail.

Here is the cascade, in plain language.

Step 1

Estrogen declines

→

Step 2

CD38 enzyme overactivates

→

Step 3

NAD⁺ reserves depleted

→

Step 4

Brain energy failure

When estrogen drops, it triggers the overactivation of an enzyme called CD38. CD38 essentially consumes your NAD⁺ — nicotinamide adenine dinucleotide — the coenzyme your mitochondria need to produce cellular energy. By the time a woman reaches her mid-40s, her NAD⁺ levels have typically dropped 40–50% from their peak.

The brain consumes 20% of the body's total energy output. It is the first system to experience a brownout when cellular fuel runs low. Brain fog isn't a vague feeling — it is a specific, measurable energy deficit in the prefrontal cortex.

The prefrontal cortex — the part of your brain responsible for word retrieval, executive function, decision-making, and complex thought — is the most energy-hungry region in the body. When NAD⁺ drops, it is starved of fuel first. This is not a coincidence. It is the biological explanation for exactly what you are experiencing.

40–50%\n

Average NAD⁺ decline by midlife

20%\n

Of total body energy consumed by the brain

2.5×\n

Faster ovarian aging vs. rest of the body

What this feels like

The Symptoms Are Specific. So Is the Biology.

Women in perimenopause describe cognitive symptoms in remarkably consistent language. Not because they have read the same articles. Because the underlying biology is the same. The prefrontal cortex has a specific failure signature when it is fuel-deprived — and it produces a specific set of experiences.

I know exactly what I want to say. The word is right there. And then it's just gone.

I used to be the sharpest person in the room. Now I feel like I'm performing competence I don't actually have.

My brain is exhausted by noon. My body still has hours left in it. The mismatch is terrifying.

I read the same paragraph three times. I still don't know what it says. I used to devour books.

These are not descriptions of aging. They are descriptions of a specific energy deficit in a specific brain region. Word retrieval failure, processing speed reduction, executive function degradation — these map directly onto the cognitive demands of the prefrontal cortex, and directly onto the NAD⁺-dependent processes it relies on.

Why this matters

This is also why no amount of espresso fixes it. Caffeine stimulates the nervous system. It does not restore mitochondrial ATP production. It borrows against tomorrow's energy to fund today's, without addressing the fuel supply at all. The brain isn't tired. It is depleted.

The second failure

The Cholinergic System Loses Its Anchor

The cognitive impact of perimenopause doesn't stop at energy depletion. Estrogen also acts as a primary regulator of the cholinergic system — the network of neurons and receptors that govern learning, memory, and the speed at which your brain processes information.

Acetylcholine is the neurotransmitter at the center of this system. Estrogen supported its synthesis and protected the receptors that receive it. When estrogen drops, acetylcholine synthesis drops with it. Processing speed slows. Word retrieval — which depends on rapid, high-fidelity signaling across neural networks — becomes unreliable.

This is why cognitive symptoms in perimenopause are not random. They follow a pattern: verbal fluency goes first, followed by processing speed, followed by working memory under stress. This is the cholinergic failure signature.

The hardware is completely intact. The failure point is metabolic and neurochemical. Restoring the substrate — NAD⁺ and the acetylcholine precursors that estrogen used to regulate — restores the function.

What you were told vs. what is true

You Were Not Imagining It.

Only 7% of medical residents feel adequately prepared to treat menopausal patients. Cognitive symptoms of perimenopause are consistently underdiagnosed, frequently dismissed as anxiety or depression, and almost never explained mechanistically to the women experiencing them.

You were told it was stress. You were told it was getting older. You were told to sleep more, drink less coffee, take a multivitamin. None of these addressed the actual mechanism — because the actual mechanism was never explained to you.

The estrogen → CD38 → NAD⁺ → mitochondrial failure pathway is not a hypothesis. It is a documented, peer-reviewed biological cascade. The cognitive symptoms that result from it are not vague or subjective. They are predictable, specific, and addressable.

The Finally. position

Your fatigue is not weakness. Your brain fog is not aging. Your lost words are not a sign of what's coming. They are a sign of a specific, measurable cellular depletion — and cellular depletion has a cellular solution.

The path forward

What Addressing the Mechanism Actually Looks Like

Understanding the mechanism reframes the solution. If the problem is NAD⁺ depletion driven by CD38 overactivation, the intervention needs to bypass that bottleneck and restore cellular fuel directly.

NMN (nicotinamide mononucleotide) is a direct NAD⁺ precursor — meaning it converts to NAD⁺ in the cell without going through the enzymatic steps that CD38 compromises. At a clinically relevant dose of 500mg, it restores mitochondrial ATP production in the prefrontal cortex. Not by stimulating the nervous system. By returning the fuel supply to normal.

This takes time. NAD⁺ levels don't recover overnight. But the mechanism is not mysterious, the timeline is predictable, and the outcome — restored cellular energy, reduced cognitive fog, more reliable word retrieval — is the logical result of addressing the underlying cause rather than managing the downstream symptoms.

Yoshino, J. et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. · Camacho-Pereira, J. et al. (2016). CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction. Cell Metabolism. · Mori, K. et al. (2009). Improving effects of Lion's Mane on mild cognitive impairment. Phytotherapy Research.

\n\n

Finally.

The first formula built
for this specific depletion.\n

500mg NMN. Third-party tested. Formulated for the estrogen–NAD⁺ decline of perimenopause — not general aging, not biohackers. You.

\nSee the formula →\n

\n","cognitive-function-decline-in-perimenopausal-women","gid://shopify/Article/573333012678","2026-05-27T01:29:26Z","Cognitive function decline in perimenopausal women",{"_13":14},"description","cart",["P",55],"isLoggedIn",["P",57],"footer",["P",59],"header",{"_64":76,"_77":78},"publicStoreDomain","xvs17q-yc.myshopify.com","shop",["P",65],"consent",{"_68":-7,"_69":70,"_71":24,"_72":73,"_74":75},"checkoutDomain","storefrontAccessToken","b480f61b25283cb5781d87c23ca6b8b3","withPrivacyBanner","country","US","language","EN",{"_37":108,"_44":109,"_53":110,"_111":112,"_113":114},"menu",{"_37":79,"_80":81},"gid://shopify/Menu/237062291654","items",[82,83,84],{"_37":102,"_86":-5,"_88":103,"_11":104,"_91":105,"_93":106,"_80":107},{"_37":96,"_86":-5,"_88":97,"_11":98,"_91":99,"_93":100,"_80":101},{"_37":85,"_86":87,"_88":89,"_11":90,"_91":92,"_93":94,"_80":95},"gid://shopify/MenuItem/567422877894","resourceId","gid://shopify/Page/117720481990","tags",[],"Contact","type","PAGE","url","https://finally.health/pages/contact",[],"gid://shopify/MenuItem/567422845126",[],"Catalog","CATALOG","https://finally.health/collections/all",[],"gid://shopify/MenuItem/567422812358",[],"Home","FRONTPAGE","https://finally.health/",[],"gid://shopify/Shop/73617670342","Finally.","","primaryDomain",{"_93":116},"brand",{"_115":-5},"logo","https://finally.health"]